Literature DB >> 2833558

A human inhibitor of tumor necrosis factor alpha.

P Seckinger1, S Isaaz, J M Dayer.   

Abstract

Urine of some febrile patients exhibits a TNF-alpha inhibitory activity (TNF-alpha INH), sensitive to heat and trypsin, with an apparent mol wt of 40-60 X 10(3) and a pI range of 5.5-6.1. As for the Il-1 INH, the TNF INH activity involves a competitive mechanism of action suggesting the existence of a family of negative feedback-regulating molecules interfering with cytokines actions.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2833558      PMCID： PMC2188924          DOI： 10.1084/jem.167.4.1511

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  10 in total

Review 1.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

Review 2.  Interleukin-1 inhibitors.

Authors:  P Seckinger; J M Dayer
Journal:  Ann Inst Pasteur Immunol       Date:  1987 May-Jun

3.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

4.  Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s).

Authors:  J F Balavoine; B de Rochemonteix; K Williamson; P Seckinger; A Cruchaud; J M Dayer
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

5.  A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha.

Authors:  P Seckinger; K Williamson; J F Balavoine; B Mach; G Mazzei; A Shaw; J M Dayer
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

6.  Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.

Authors:  G E Nedwin; L P Svedersky; T S Bringman; M A Palladino; D V Goeddel
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

7.  A urine inhibitor of interleukin 1 activity that blocks ligand binding.

Authors:  P Seckinger; J W Lowenthal; K Williamson; J M Dayer; H R MacDonald
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

8.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

9.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307
  10 in total
  51 in total

1.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

Review 2.  Cytokines, receptors, and inhibitors.

Authors:  G Gehr; T Braun; W Lesslauer
Journal:  Clin Investig       Date:  1992-01

Review 3.  Use of immune modulators in nonspecific therapy of bacterial infections.

Authors:  M T Vogels; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  A serum factor that suppresses the cytotoxic function of cytokine-stimulated human eosinophils.

Authors:  D S Silberstein; M S Minkoff; A A Creasey; J R David
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

Review 5.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

Review 6.  Immune modulation in heart failure: past challenges and future hopes.

Authors:  Jose H Flores-Arredondo; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Curr Heart Fail Rep       Date:  2011-03

7.  Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development.

Authors:  H G Welgus; E J Campbell; J D Cury; A Z Eisen; R M Senior; S M Wilhelm; G I Goldberg
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

8.  Effect of tumor necrosis factor receptor binding protein on cell infiltration induced by lipopolysaccharide and Sephadex beads in guinea pig lung.

Authors:  D M Conroy; J N Francischi; P Sirois
Journal:  Inflammation       Date:  1995-04       Impact factor: 4.092

9.  Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia.

Authors:  H Redl; G Schlag; G R Adolf; B Natmessnig; J Davies
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

10.  Activated macrophages depress the contractility of rabbit carotids via an L-arginine/nitric oxide-dependent effector mechanism. Connection with amplified cytokine release.

Authors:  C Bernard; B Szekely; I Philip; E Wollman; D Payen; A Tedgui
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.